Skip to content
Awesome – Lifestyle
Author:
Aprea Therapeutics
Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium
September 22, 2026
Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
September 10, 2026
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs
August 28, 2026
Aprea Therapeutics Announces Second Quarter 2026 Financial Results
August 12, 2026
Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors
June 1, 2026
Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting
April 29, 2026
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement
April 1, 2026
Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement
March 30, 2026
Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial
March 30, 2026
Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
March 16, 2026